Moghimi S, Riazi Esfahani M, Maghsoudipour M
Farabi Eye Research Center, Department of Ophthalmology, Tehran University of Medical Sciences, Quazvin Square, Tehran, Iran.
Eur J Ophthalmol. 2007 Jul-Aug;17(4):660-5. doi: 10.1177/112067210701700428.
To evaluate the efficacy and safety of aniridia posterior chamber intraocular lens (PCIOL) in traumatic aniridia and aphakia in vitrectomized eyes.
Four aphakic patients with traumatic aniridia and previous pars plana vitrectomy (PPV) due to posterior segment trauma enrolled in the study, and had secondary implantation of an aniridia PCIOL. Two patients were men and two women with mean age of 39.25 years. Complete ophthalmic examinations, including preoperative and postoperative visual acuity in dark and light, glare disability, visual function (using VF-9 questions modified from VF-14), stereopsis, and contrast sensitivity in 3, 6, 12, and 18 cycle per degree frequencies, were done for all patients. Postoperative intraocular pressure (IOP), IOL centration, and intraocular inflammation were monitored. Mean follow-up was 12.25 months (range 7 to 15 months).
Visual acuity improved in all four patients, especially in the light. Glare was subjectively reduced in all of them. Stereopsis was measurable in three of them postoperatively. Contrast sensitivity improved in all patients, especially in brightness and lower frequencies. All four eyes had improved VF-9. All eyes achieved the desired anatomic results. Two cases developed elevated IOP early after surgery. In one eye, IOP elevation was transient and controlled with antiglaucoma medication, but the other eye, which had secondary glaucoma from previous trauma, required cyclophotocoagulation for the IOP to be controlled. No patient developed chronic uveitis or redetachment.
The aniridia PCIOL can overcome aphakia, reduce glare, and increase visual function, contrast sensitivity, and stereopsis in vitrectomized eyes with traumatic aniridia. Although this kind of IOL appears safe, some disadvantages are secondary glaucoma and reduced visibility of peripheral fundus, and caution should be used in its implantation until more patients with longer follow-up are studied.
评估无虹膜后房型人工晶状体(PCIOL)在玻璃体切除术后眼外伤无虹膜和无晶状体眼中的有效性和安全性。
4例因后段外伤导致外伤性无虹膜且曾行前段玻璃体切除术(PPV)的无晶状体患者纳入本研究,并二期植入无虹膜PCIOL。2例男性,2例女性,平均年龄39.25岁。对所有患者进行了全面的眼科检查,包括术前和术后暗光及明视下视力、眩光障碍、视觉功能(使用从VF - 14修改而来的VF - 9问题)、立体视以及每度3、6、12和18周期频率下的对比敏感度。监测术后眼压(IOP)、人工晶状体中心定位和眼内炎症。平均随访时间为12.25个月(范围7至15个月)。
所有4例患者视力均有改善,尤其是在明视下。所有人主观上眩光均减轻。其中3例术后可测量立体视。所有患者对比敏感度均提高,尤其是在明亮环境和较低频率下。所有4只眼的VF - 9均有改善。所有眼均获得了理想的解剖学结果。2例患者术后早期眼压升高。1只眼中,眼压升高是短暂的,通过抗青光眼药物得以控制,但另一只眼因既往外伤继发青光眼,需要进行睫状体光凝术来控制眼压。无患者发生慢性葡萄膜炎或视网膜再脱离。
无虹膜PCIOL可克服无晶状体状态,减少眩光,并提高玻璃体切除术后外伤性无虹膜眼的视觉功能、对比敏感度和立体视。尽管这种人工晶状体似乎安全,但存在一些缺点,如继发性青光眼和周边眼底可见度降低,在有更多患者接受更长时间随访研究之前,植入时应谨慎。